The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of eribulin (ERB) and cyclophosphamide (CTX) in metastatic breast cancer (MBC).
Thach-Giao Truong
No relevant relationships to disclose
Michael Pelayo
No relevant relationships to disclose
Jennifer A. Grabowsky
No relevant relationships to disclose
Michelle E. Melisko
No relevant relationships to disclose
Mark Jesus Mendoza Magbanua
No relevant relationships to disclose
Mark M. Moasser
No relevant relationships to disclose
Anne Reinert
No relevant relationships to disclose
Jimmy Hwang
No relevant relationships to disclose
John W. Park
No relevant relationships to disclose
Pamela N. Munster
No relevant relationships to disclose
Hope S. Rugo
Research Funding - Eisai